Seres Therapeutics, Inc. (MCRB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 1.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.08% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
- Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
- Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
- Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
- We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
- Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Seres Therapeutics, Inc..
Full MCRB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.